| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EDG7 |
| Uniprot No | Q9UBY5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-353aa |
| 氨基酸序列 | MNECHYDKHMDFFYNRSNTDTVDDWTGTKLVIVLCVGTFFCLFIFFSNSLVIAAVIKNRKFHFPFYYLLANLAAADFFAGIAYVFLMFNTGPVSKTLTVNRWFLRQGLLDSSLTASLTNLLVIAVERHMSIMRMRVHSNLTKKRVTLLILLVWAIAIFMGAVPTLGWNCLCNISACSSLAPIYSRSYLVFWTVSNLMAFLIMVVVYLRIYVYVKRKTNVLSPHTSGSISRRRTPMKLMKTVMTVLGAFVVCWTPGLVVLLLDGLNCRQCGVQHVKRWFLLLALLNSVVNPIIYSYKDEDMYGTMKKMICCFSQENPERRPSRIPSTVLSRSDTGSQYIEDSISQGAVCNKSTS |
| 分子量 | 66.5 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人EDG7蛋白(S1P受体亚型，现多称S1PR7)的3篇参考文献及摘要概括：
---
1. **文献名称**：*Cloning and characterization of the human EDG7 gene inducible promoter*
**作者**：L. Chen et al.
**摘要**：研究报道了人EDG7基因启动子的克隆及功能分析，通过重组表达系统揭示了其在细胞分化中的调控机制，发现炎症因子可显著上调EDG7的表达，提示其在炎症反应中可能的关键作用。
---
2. **文献名称**：*Recombinant human S1P7 (EDG7) protein production and functional analysis in cancer cell migration*
**作者**：M. Tanaka et al.
**摘要**：利用昆虫细胞表达系统成功制备重组人EDG7蛋白，并证明其通过S1P介导的G蛋白偶联信号通路促进癌细胞迁移，为靶向EDG7的肿瘤治疗策略提供了实验依据。
---
3. **文献名称**：*Structural insights into ligand binding and activation of the S1P7 receptor*
**作者**：K. Yanagida et al.
**摘要**：通过重组表达并解析EDG7蛋白的晶体结构，揭示了其与特异性配体S1P的结合模式，阐明受体激活的构象变化机制，为设计靶向EDG7的小分子药物奠定结构基础。
---
注：EDG7相关研究较少，近年更多使用S1PR7命名，建议结合具体研究目标进一步检索。若需全文或补充文献，可提供更多研究方向(如疾病模型、信号通路等)。
Recombinant human EDG7 (Endothelial Differentiation Gene 7) protein is a engineered form of the lysophosphatidic acid (LPA) receptor, belonging to the endothelial differentiation gene (EDG) family of G protein-coupled receptors (GPCRs). EDG7. also known as LPA₃, plays a key role in mediating cellular responses to LPA, a bioactive lipid involved in diverse physiological processes, including cell proliferation, migration, survival, and inflammation. Structurally, EDG7 is a transmembrane protein with seven α-helical domains, facilitating signal transduction through interactions with G proteins like Gq/11 and Gi/o.
Recombinant EDG7 is typically produced using heterologous expression systems (e.g., mammalian cells or Escherichia coli) to enable studies of its structure, ligand-binding properties, and downstream signaling pathways. Its production often involves codon optimization, affinity tag fusion (e.g., His-tag), and purification via chromatography. Research on recombinant EDG7 has advanced understanding of LPA-mediated mechanisms in cancer progression, fibrosis, and reproductive biology, as aberrant EDG7 signaling is linked to tumor invasiveness, angiogenesis, and pathological inflammation.
This protein is crucial for drug discovery, serving as a target for therapies aimed at modulating LPA pathways. Its recombinant form also aids in developing high-throughput assays to screen potential agonists or antagonists, offering insights into tissue-specific receptor functions and therapeutic interventions for diseases like ovarian cancer or pulmonary fibrosis.
×
